Furthermore, in breast cancers, an evaluation of TILs based on hematoxylin and eosin staining and morphology is highly recommended, as well as in non-small cell lung cancers where CD8+ and CD45RO+ lymphocyte markers appear to be promising candidates for improving TNM [5,34,35]. This evidence concerns the gene CD8A and non-small cell lung carcinoma.